User profiles for J. Pater
Joe PaterProfessor of Linguistics, University of Massachusetts Verified email at linguist.umass.edu Cited by 7530 |
Clinical Predictive Value of the in Vitro Cell Line, Human Xenograft, and Mouse Allograft Preclinical Cancer Models
T Voskoglou-Nomikos, JL Pater, L Seymour - Clinical cancer research, 2003 - AACR
Purpose: We looked at the value of three preclinical cancer models, the in vitro human cell
line, the human xenograft, and the murine allograft, to examine whether they are reliable in …
line, the human xenograft, and the murine allograft, to examine whether they are reliable in …
Structure and substance in artificial‐phonology learning, part I: Structure
E Moreton, J Pater - Language and linguistics compass, 2012 - Wiley Online Library
Artificial analogues of natural‐language phonological patterns can often be learned in the
lab from small amounts of training or exposure. The difficulty of a featurally‐defined pattern …
lab from small amounts of training or exposure. The difficulty of a featurally‐defined pattern …
Constraint conflict in cluster reduction
… Dorsal-specific faithfulness is documented for onset selection in truncation in Pater (1997),
but we have yet to find a parallel case in onset selection in cluster reduction. This may be due …
but we have yet to find a parallel case in onset selection in cluster reduction. This may be due …
[PDF][PDF] Interpreting the significance of changes in health-related quality-of-life scores
…, G Rodrigues, J Myles, B Zee, J Pater - Journal of clinical …, 1998 - academia.edu
Purpose: To determine the significance to patients of changes in health-related quality-of-life
(HLQ) scores assessed by the European Organization for Research and Treatment of …
(HLQ) scores assessed by the European Organization for Research and Treatment of …
[HTML][HTML] Erlotinib in lung cancer—molecular and clinical predictors of outcome
…, M Whitehead, K Ding, J Pater… - … England Journal of …, 2005 - Mass Medical Soc
Background A clinical trial that compared erlotinib with a placebo for non–small-cell lung
cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from …
cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from …
[HTML][HTML] A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
…, P Therasse, MJ Palmer, JL Pater - … England Journal of …, 2003 - Mass Medical Soc
Background In hormone-dependent breast cancer, five years of postoperative tamoxifen
therapy — but not tamoxifen therapy of longer duration — prolongs disease-free and overall …
therapy — but not tamoxifen therapy of longer duration — prolongs disease-free and overall …
Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial
…, J Wunder, R Kandel, K Goddard, A Sadura, J Pater… - The Lancet, 2002 - thelancet.com
… J Wunder and A Davis provided the prognostic variables used to describe the study sample,
… A Sadura, J Pater, and B Zee verified and analysed the data, and contributed to completion …
… A Sadura, J Pater, and B Zee verified and analysed the data, and contributed to completion …
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17
…, DA Cameron, MJ Palmer, JL Pater - Journal of the …, 2005 - academic.oup.com
Background: Most recurrences in women with breast cancer receiving 5 years of adjuvant
tamoxifen occur after 5 years. The MA.17 trial, which was designed to determine whether …
tamoxifen occur after 5 years. The MA.17 trial, which was designed to determine whether …
Are long-chain polyunsaturated fatty acids essential nutrients in infancy?
We investigated whether the disparity in neural maturation between breastfed and formula-fed
term infants could be corrected by the addition of fish oil, a source of docosahexaenoic …
term infants could be corrected by the addition of fish oil, a source of docosahexaenoic …
Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.
E Rapp, JL Pater, A Willan, Y Cormier… - Journal of Clinical …, 1988 - ascopubs.org
The survival benefit of combination chemotherapy to patients with advanced non-small-cell
carcinoma of the lung (NSCLC) is controversial. To study this question, the National Cancer …
carcinoma of the lung (NSCLC) is controversial. To study this question, the National Cancer …